Opus Genetics, Inc.
IRD - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$443.04M
Close$
$-0.22
104.8% downside
Current Fair Value
104.8% downsideOvervalued by 104.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $443.04 Million |
|---|---|
| Enterprise Value | $389.16 Million |
| Earnings per Share | $-0.8 |
| Beta | 0.62 |
| Outstanding Shares | 95,483,280 |
Return
| Return on Equity | 828.66% |
|---|---|
| Return on Assets | -115.75% |
| Return on Invested Capital | -48.87% |
Valuation & Multiples
| P/E Ratio | -3.29 |
|---|---|
| PEG | -36.02 |
| Price to Sales | - |
| Price to Book Ratio | -4.64 |
| Enterprise Value to Revenue | 75.93 |
| Enterprise Value to EBIT | -9.33 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -2.69 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.16
Consensus analyst estimateRevenue Estimate
$2.63 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.14
Consensus analyst estimateRevenue Estimate
$1.55 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Ocuphire Pharma Inc
28 employees
CEO: Douglas Swirsky
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering...